These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2866061)

  • 1. Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.
    Gibson PR; Jewell DP
    Clin Sci (Lond); 1985 Aug; 69(2):177-84. PubMed ID: 2866061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.
    Aparicio-Pagés MN; Verspaget HW; Hafkenscheid JC; Crama-Bohbouth GE; Peña AS; Weterman IT; Lamers HW
    Gut; 1990 Sep; 31(9):1030-2. PubMed ID: 1976576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of leucocyte motility by drugs used in ulcerative colitis.
    Rhodes JM; Bartholomew TC; Jewell DP
    Gut; 1981 Aug; 22(8):642-7. PubMed ID: 6116649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased suppressor cell activity in inflammatory bowel disease.
    Holdstock G; Chastenay BF; Krawitt EL
    Gut; 1981 Dec; 22(12):1025-30. PubMed ID: 6119275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of prostaglandin synthetase in human rectal mucosa.
    Hawkey CJ; Lo Casto M
    Gut; 1983 Mar; 24(3):213-7. PubMed ID: 6131017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
    Kimura I; Kumamoto T; Matsuda A; Kataoka M; Kokuba Y
    Arzneimittelforschung; 1998 Oct; 48(10):1007-11. PubMed ID: 9825118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes.
    Shanahan F; Niederlehner A; MacDermott RP; Stenson WF; Kane MG; Targan S
    Immunopharmacology; 1986 Apr; 11(2):111-8. PubMed ID: 2872187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.
    Allgayer H; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(4):449-51. PubMed ID: 6428914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Products of the lipoxygenase pathway in human natural killer cell cytotoxicity.
    Rossi P; Lindgren JA; Kullman C; Jondal M
    Cell Immunol; 1985 Jun; 93(1):1-8. PubMed ID: 2986854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nature of the natural killer (NK) cell of human intestinal mucosa and mesenteric lymph node.
    Gibson PR; Jewell DP
    Clin Exp Immunol; 1985 Jul; 61(1):160-8. PubMed ID: 2412737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
    Bird HA
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of aminosalicylic acid derivatives on nitric oxide in a cell-free system.
    Reynolds PD; Middleton SJ; Shorthouse M; Hunter JO
    Aliment Pharmacol Ther; 1995 Oct; 9(5):491-5. PubMed ID: 8580268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible inhibition of lymphokine-activated killer cell activity by lipoxygenase-pathway inhibitors.
    Sibbitt WL; Imir T; Bankhurst AD
    Int J Cancer; 1986 Oct; 38(4):517-21. PubMed ID: 3019899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human natural killer cell activity is reversibly inhibited by antagonists of lipoxygenation.
    Seaman WE
    J Immunol; 1983 Dec; 131(6):2953-7. PubMed ID: 6417236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products.
    Tornhamre S; Edenius C; Smedegård G; Sjöquist B; Lindgren JA
    Eur J Pharmacol; 1989 Oct; 169(2-3):225-34. PubMed ID: 2572437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cytotoxicity by sulfasalazine. I. Sulfasalazine inhibits spontaneous cell-mediated cytotoxicity by peripheral blood and intestinal mononuclear cells from control and inflammatory bowel disease patients.
    MacDermott RP; Kane MG; Steele LL; Stenson WF
    Immunopharmacology; 1986 Apr; 11(2):101-9. PubMed ID: 2872186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
    Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y
    Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of antibody secretion by 5-aminosalicylic acid.
    MacDermott RP; Schloemann SR; Bertovich MJ; Nash GS; Peters M; Stenson WF
    Gastroenterology; 1989 Feb; 96(2 Pt 1):442-8. PubMed ID: 2562949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis.
    Roediger W; Schapel G; Lawson M; Radcliffe B; Nance S
    Biochem Pharmacol; 1986 Jan; 35(2):221-5. PubMed ID: 2867767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of sulphasalazine and its metabolites on prostaglandin production by human mononuclear cells.
    Punchard NA; Boswell DJ; Greenfield SM; Thompson RP
    Biochem Pharmacol; 1992 Jun; 43(11):2369-76. PubMed ID: 1351726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.